Company: IMCR
Filing Date: 2025-03-17
Form Type: 424B7
Source: 0001140361-25-008917
Chunk: 122

Company: Immunocore Holdings plc
Filing Date: 2025-03-17
Form: 424B7
Chunk 122
---
 Act, amending the list of selling securityholders to include the pledgee, transferee or other successors in interest as selling securityholders under this prospectus supplement. The selling securityholders also may transfer the notes or note conversion ADSs in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus supplement. In connection with the sale of our notes or note conversion ADSs or interests therein, the selling securityholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the notes or the note conversion ADSs in the course of hedging the positions they assume. The selling securityholders may also sell notes or note conversion ADSs short and if such short sale shall take place after the date of this prospectus supplement, the selling securityholders may deliver notes or note conversion ADSs covered by this prospectus supplement to close out short positions and to return borrowed notes or note conversion ADSs in connection with such short sales. The selling securityholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the

S-67

#### TABLE OF CONTENTS
delivery to such broker-dealer or other financial institution of notes or note conversion ADSs offered by this prospectus supplement, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus supplement (as supplemented or amended to reflect such transaction). Notwithstanding the foregoing, the selling securityholders have been advised that they may not use notes or note conversion ADSs registered on the registration statement to cover short sales of our notes or note conversion ADSs made prior to the date of this prospectus supplement.

The aggregate proceeds to the selling securityholders from the sale of the notes or the note conversion ADSs offered by them will be the purchase price of the notes less discounts or commissions, if any. The selling securityholders reserve the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of notes or note conversion ADSs to be made directly or through agents.

The selling securityholders also may resell all or a portion of the notes or the note conversion ADSs in reliance upon Rule 144 under the Securities Act, provided that they meet the criteria and conform to the requirements of that rule.

The selling securityholders and any broker-dealers or agents that participate in the sale of